Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Precision Radiotherapy at University Pointe
mi
from
West Chester, OH
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Precision Radiotherapy at University Pointe
mi
from
West Chester, OH
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Mount Carmel St. Ann's Cancer Center
mi
from
Westerville, OH
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Mount Carmel St. Ann's Cancer Center
mi
from
Westerville, OH
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Clinton Memorial Hospital
mi
from
Wilmington, OH
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Clinton Memorial Hospital
mi
from
Wilmington, OH
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Genesis - Good Samaritan Hospital
mi
from
Zanesville, OH
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Legacy Good Samaritan Hospital & Comprehensive Cancer Center
mi
from
Portland, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Legacy Good Samaritan Hospital & Comprehensive Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Adventist Medical Center
mi
from
Portland, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Adventist Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists at Rose Quarter Cancer Center
mi
from
Portland, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists at Rose Quarter Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
AnMed Cancer Center
mi
from
Anderson, SC
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
AnMed Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Luther Midlelfort Hospital
mi
from
Eau Claire, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Luther Midlelfort Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Midelfort Clinic - Luther
mi
from
Eau Claire, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Midelfort Clinic - Luther
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Oncology
mi
from
Casper, WY
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Oncology
mi
from
Casper, WY
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
A Phase I Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
A Phase I Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
A Phase II Study to Determine the Efficacy of Tarceva® (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
A Phase II Study to Determine the Efficacy of Tarceva® (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute - St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute - St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
John Wayne Cancer Institute at St. John's Health Center
mi
from
Santa Monica, CA
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
John Wayne Cancer Institute at St. John's Health Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
NorthShore University Health System
mi
from
Chicago, IL
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
NorthShore University Health System
mi
from
Chicago, IL
Click here to add this to my saved trials
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Rhinological Outcomes in Endonasal Pituitary Surgery
Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Barcelona,
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Barcelona,
Click here to add this to my saved trials
Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)
Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy
Status: Enrolling
Updated:  12/31/1969
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)
Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy
Status: Enrolling
Updated: 12/31/1969
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Quality of Recovery Awake Versus Asleep Craniotomy
Quality of Recovery Following Awake Craniotomy Versus Craniotomy Performed Under General Anesthesia
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Quality of Recovery Awake Versus Asleep Craniotomy
Quality of Recovery Following Awake Craniotomy Versus Craniotomy Performed Under General Anesthesia
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials